#Ireland #Dublin #pharmaceuticals #Mallinckrodt #Endo

Mallinckrodt and Endo Merger Approved: A New Era in the Pharmaceutical Industry

In a significant move for the global pharmaceutical landscape, shareholders of Mallinckrodt plc and Endo, Inc. have given the green light to their proposed merger. This strategic combination is set to create a diversified leader in the pharmaceutical sector, aiming to deliver enhanced value to shareholders, customers, and patients worldwide.

Merger Details

On June 13, 2025, both firms announced that they successfully received the necessary approvals from their shareholders for the merger, which involves a mix of cash and stock. The approval marks a crucial step towards the implementation of their plans to integrate operations and streamline services effectively.

Following the shareholder nod, Mallinckrodt will be seeking the Irish High Court's confirmation for a scheme of arrangement soon. In July, a court hearing has been scheduled, during which the conditions for the merger's finalization will be examined. Should the court sanction the deal, the merger is anticipated to close shortly after, driving excitement among stakeholders.

A New Global Headquarters

Post-merger, Mallinckrodt's headquarters located in Dublin, Ireland, is set to serve as the new global base of operations for the combined entity. This decision signals the company's commitment to enhancing its operational capacity in Europe and beyond.

Siggi Olafsson, the current President and CEO of Mallinckrodt, is poised to lead the new company. His vision includes accelerating value creation and delivering innovative solutions in the pharmaceutical field, ensuring better health outcomes for patients around the globe.

Strategic Plans

As outlined in earlier announcements, the new entity will immediately revolve around the combination of their respective generic pharmaceuticals segments and Endo's sterile injectables business. However, leaders intend to make a strategic separation of these segments at a later date, contingent on approvals from the company's Board of Directors and other regulatory conditions.

This merger signifies more than just a combination of assets; it represents a fusion of expertise and resources aimed at enhancing product offerings for patients. Scott Hirsch, Interim CEO of Endo, expressed optimism about the merger's strategic alignment, emphasizing the potential to deliver improved outcomes for patients and sustainable long-term value for all stakeholders involved.

Financial Advisors and Legal Counsel

The intricate details of the merger have been choreographed with the assistance of key financial and legal advisors. Lazard is the financial advisor for Mallinckrodt, while Goldman Sachs & Co. LLC undertakes the same role for Endo. Legal expertise is being provided by Wachtell, Lipton, Rosen & Katz, along with Hogan Lovells and Arthur Cox for Mallinckrodt, and several other law firms for Endo.

What Lies Ahead

As the merger progresses, both firms aim to not only solidify their market presence but also to ensure their operational infrastructures can efficiently support the anticipated growth. Investors and stakeholders are urged to keep an eye on developments as they unfold, with the collective aim of achieving an enriched portfolio of pharmaceuticals targeted towards addressing critical health needs.

In summary, the merger between Mallinckrodt and Endo opens a new chapter in the pharmaceutical industry, with the potential to expand their reach and innovation capabilities significantly. Both firms look forward to achieving positive outcomes for the medical community and patients everywhere through this strategic alignment.

For further insights, stakeholders are encouraged to review updates on the investor relations sections of both Mallinckrodt and Endo's websites to monitor the progress and any significant developments related to the merger.